Evidence map›Paper›PMID 41113040›Full record

ArticleAmerican journal of translational research2025

Mic60/Mitofilin inhibitor, Miclxin, induces rat H9C2 cardiomyoblast death by inhibiting the removal of damaged mitochondria.

Muhammad S Khan, Somayyeh Nasiripour, Michele Oyarzabal, Swati Banerjee, Kumar Sharma, Manzoor A Bhat, Jean C Bopassa

Abstract read
In one paragraph

Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad S KhanDepartment of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.
Somayyeh NasiripourDepartment of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.
Michele OyarzabalDepartment of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.
Swati BanerjeeDepartment of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.
Kumar SharmaCenter for Precision Medicine, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.
Manzoor A BhatDepartment of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.
Jean C BopassaDepartment of Cellular and Integrative Physiology, School of Medicine, University of Texas Health Science Center at San Antonio San Antonio, TX 78229, USA.

Funding

PATHOBIOLOGY OF OCCLUSIVE VASCULAR DISEASET32HL007446 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jean Chrisostome Bopassa · 1985 to 2026
$8.9M
Degradation of Mitochondrial Inner Membrane Protein Disrupts the Structural Interaction between Mitofilin and Cyclophilin D and Determines the Extent of Ischemia/reperfusion injuryR01HL138093 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BOPASSA, JEAN CHRISOSTOME · 2017 to 2021
$1.9M
NHLBI NIH HHS R01 HL138093NHLBI NIH HHS T32 HL007446
6 · The paper itself

Abstract

Mitochondrial dysfunction is a hallmark of various pathologic conditions, including ischemia/reperfusion injury, stroke, myocardial infarction, neurodegeneration and metabolic syndrome. As with all biological organelles, the function of mitochondria is tightly linked to their structure. The inner mitochondrial membrane is a highly regulated membrane with a large surface area that hosts the electron transport chain machinery, generates the membrane potential necessary for ATP generation, and forms the signature cristae folds of mitochondria. The mitochondrial inner membrane protein (Mitofilin/Mic60) is part of a large complex that constitutes the mitochondrial inner membrane organizing system, which is critical in maintaining mitochondrial architecture and function. Recent evidence has shown that Mic60/Mitofilin elimination during reperfusion determines the extent of myocardial infarct size after ischemia/reperfusion. Here, we investigated the effects and mechanisms of action of Miclxin, a novel Mic60/Mitofilin inhibitor using H9c2 cardiomyoblasts. Cultured rat H9c2 cardiomyoblasts were incubated with 0, 5, 10, or 20 μM of Miclxin. Cell viability was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assays, and cell death was determined by flow cytometry using propidium iodide dye. Mitochondrial membrane potential was measured using MitoTracker Red CMXROS assay kits, and mitophagy in mitochondria was detected using Mitophagy Detection Kits. Mitochondrial morphology was assessed using electron microscopy, and proteins were measured by Western blot analyses and immunofluorescence staining. After 24 hours of treatment, Miclxin decreased cell viability in a dose-dependent manner and reduced the number of viable cells measured with MTT assays. This effect was associated with pronounced reduction of Mic60 protein levels measured by Western blots and immunocytochemistry. Miclxin's reduction of cell viability was related to its inhibition of mitochondrial elimination by mitophagy. Our findings suggest that Miclxin decreases levels of Mic60, and thereby reduces cell viability by increasing structural damage and dysfunction in mitochondria via impairment of mitophagy.

Indexed as

cell viabilityH9C2 rat cardiomyomyoblastsMic60/Mitofilin proteinMiclxinmitochondriamitophagy

Identifiers

PMID41113040
PMCPMC12531562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.